Business Wire1d
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patient…
Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
CEL-SCI announces neoadjuvant nivolumab plus chemotherapy study published
CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...
Targeted Oncology12d
Understanding the Use of Nivolumab in the Current Upper GI Landscape
David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...
Targeted Oncology1d
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
MedPage Today on MSN5d
De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBC
Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...
Labiotech.eu3d
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
Medscape10d
Tislelizumab Receives First-Line Nod for Unresectable/Metastatic ESCC
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
Business Wire5d
Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications
resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be eligible for treatment with Bristol Myers Squibb’s OPDIVO® (nivolumab) in combination with platinum ...